ACTUATE THERAPEUTICS, INC. (ACTU)
Nasdaq · Pharmaceutical Preparations · Inc. DE
What they're doing
Between 2026-08-02 and 2026-10-31, public records show 1 signal for ACTUATE THERAPEUTICS, INC.. Most notable: 2026-10-28: Filed 8-K disclosing material agreement. Federal contract obligations over the last 24 months total $0. This summary was assembled automatically from SEC EDGAR, USAspending.gov, U.S. Senate lobbying disclosures and Wikimedia pageview counts.
Generated 2026-10-31 from public records.
Signals, last 12 months
- Material 8-K filingFiled 8-K disclosing material agreement
- Material 8-K filingFiled 8-K disclosing director or officer change
- Large insider saleTHOMSON TODD S (director) sold $1.6M of stock
- Material 8-K filingFiled 8-K disclosing material agreement
Insider transactions
| Date | Insider | Role | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-10-28 | SCHMITT DANIEL M | director | P | 140,844 | 0.36 | $50,000 |
| 2026-02-13 | SCHMITT DANIEL M | director | F | 121,874 | 4.33 | $527,714 |
| 2026-02-13 | SCHMITT DANIEL M | director | M | 272,055 | 0 | $0 |
| 2026-01-05 | THOMSON TODD S | director | S | 280,000 | 5.8 | $1,624,000 |
| 2025-06-27 | Bios Equity COF, LP | director | P | 71,428 | 7 | $499,996 |
| 2025-06-27 | BIOS Fund II, LP | director | P | 71,428 | 7 | $499,996 |
| 2025-06-27 | BIOS Actuate Co-Invest I, LP | director | P | 71,428 | 7 | $499,996 |
| 2024-08-14 | BIOS Fund II QP, LP | director | C | 61,857 | — | — |
| 2024-08-14 | BIOS Fund II QP, LP | director | C | 462,073 | — | — |
| 2024-08-14 | BIOS Fund II QP, LP | director | C | 141,457 | — | — |
| 2024-08-14 | BIOS Fund II QP, LP | director | C | 307,538 | — | — |
| 2024-08-14 | BIOS Fund II QP, LP | director | C | 525,797 | — | — |
| 2024-08-14 | BIOS Fund II QP, LP | director | P | 125,000 | 8 | $1,000,000 |
| 2024-08-14 | BIOS Fund II QP, LP | director | P | 375,000 | 8 | $3,000,000 |
| 2024-08-14 | BIOS Fund II QP, LP | director | C | 884,427 | — | — |
| 2024-08-14 | BIOS Fund II QP, LP | director | S | 2,324 | 9 | $20,916 |
| 2024-08-14 | BIOS Fund II QP, LP | director | X | 3,528 | 5.27 | $18,593 |
| 2024-08-14 | BIOS Fund II QP, LP | director | S | 17,361 | 9 | $156,249 |
| 2024-08-14 | BIOS Fund II QP, LP | director | X | 26,355 | 5.27 | $138,891 |
| 2024-08-14 | BIOS Fund II QP, LP | director | S | 5,314 | 9 | $47,826 |
| 2024-08-14 | BIOS Fund II QP, LP | director | X | 8,068 | 5.27 | $42,518 |
| 2024-08-14 | BIOS Fund II QP, LP | director | C | 573,394 | — | — |
| 2024-08-14 | BIOS Fund II QP, LP | director | C | 78,267 | — | — |
| 2024-08-14 | BIOS Fund II QP, LP | director | C | 484,638 | — | — |
| 2024-08-14 | Bios Clinical Opportunity Fund, LP | director | S | 2,324 | 8 | $18,592 |
| 2024-08-14 | Bios Clinical Opportunity Fund, LP | director | S | 17,361 | 8 | $138,888 |
| 2024-08-14 | Bios Clinical Opportunity Fund, LP | director | S | 5,314 | 8 | $42,512 |
| 2024-08-14 | BIOS Capital Management, LP | director | S | 2,324 | 8 | $18,592 |
| 2024-08-14 | BIOS Capital Management, LP | director | S | 5,314 | 8 | $42,512 |
| 2024-08-14 | BIOS Capital Management, LP | director | S | 17,361 | 8 | $138,888 |
| 2024-08-14 | BIOS Fund II, LP | director | S | 2,324 | 8 | $18,592 |
| 2024-08-14 | BIOS Fund II, LP | director | S | 5,314 | 8 | $42,512 |
| 2024-08-14 | BIOS Fund II, LP | director | S | 17,361 | 8 | $138,888 |
| 2024-08-14 | Kairos-Actuate SPV, L.P. | director | C | 146,870 | — | — |
| 2024-08-14 | Kairos-Actuate SPV, L.P. | director | C | 230,597 | — | — |
| 2024-08-14 | Kairos-Actuate SPV, L.P. | director | C | 138,889 | — | — |
| 2024-08-14 | Kairos-Actuate SPV, L.P. | director | C | 726,163 | — | — |
| 2024-08-14 | Kairos-Actuate SPV, L.P. | director | C | 1,058,318 | — | — |
| 2024-08-14 | Kairos-Actuate SPV, L.P. | director | C | 69,445 | — | — |
| 2024-08-14 | Kairos-Actuate SPV, L.P. | director | C | 132,908 | — | — |
| 2024-08-14 | Kairos-Actuate SPV, L.P. | director | C | 24,138 | — | — |
| 2024-08-14 | Kairos-Actuate SPV, L.P. | director | C | 49,984 | — | — |
| 2024-08-14 | Kairos-Actuate SPV, L.P. | director | X | 28,464 | 5.27 | $150,005 |
| 2024-08-14 | Kairos-Actuate SPV, L.P. | director | S | 18,750 | 8 | $150,000 |
| 2024-08-14 | BIOS Equity Partners III, LP | director | C | 525,797 | — | — |
| 2024-08-14 | BP Directors, LP | director | C | 78,267 | — | — |
| 2024-08-14 | BP Directors, LP | director | C | 484,638 | — | — |
| 2024-08-14 | BP Directors, LP | director | X | 8,068 | 5.27 | $42,518 |
| 2024-08-14 | BP Directors, LP | director | S | 5,314 | 9 | $47,826 |
| 2024-08-14 | BP Directors, LP | director | X | 26,355 | 5.27 | $138,891 |
Federal contracts
No federal contract actions on record for this recipient mapping.
Lobbying
No federal lobbying filings on record for this client mapping.
Public attention
No Wikipedia pageview data linked to this company.